Does Rallies show 13F holders for HBIO?

Yes. Rallies tracks hedge fund and 13F ownership data for HBIO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is HBIO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for HBIO. It does not provide personalized investment advice.

HBIO (Harvard Bioscience Inc) Stock Analysis - Hedge Fund Holdings

Harvard Bioscience Inc (HBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, HBIO trades at $5.40 with a market cap of $22.55M and a P/E ratio of -5.89. HBIO moved +0.00% today. Year to date, HBIO is -20.98%; over the trailing twelve months it is +60.52%. Its 52-week range spans $2.81 to $28.20. Analyst consensus is buy with an average price target of $6.00. Rallies surfaces HBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns HBIO stock?

Hedge funds tracked by Rallies that own HBIO include Panagora Asset. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Harvard Bioscience Inc.

HBIO Key Metrics

Key financial metrics for HBIO
Metric	Value
Price	$5.40
Market Cap	$22.55M
P/E Ratio	-5.89
EPS	$-0.91
Dividend Yield	0.00%
52-Week High	$28.20
52-Week Low	$2.81
Volume	0
Avg Volume	0
Revenue (TTM)	$85.53M
Net Income	$-9.78M
Gross Margin	58.42%

Top Hedge Funds Holding HBIO

Panagora Asset holds 120.38K shares of HBIO, changed -26.60% as of Mar 31, 2025.

Latest HBIO News

Harvard Bioscience Q1 Revenues Dip to $20.8M While Gross Margin Rises to 59% — May 12, 2026
Harvard Bioscience Sets 10-for-1 Reverse Split Effective March 13 to Boost Share Price — Mar 9, 2026
Harvard Bioscience Q4 Revenue Tops Guidance at $23.7M, EBITDA Up 27% — Feb 10, 2026

Recent HBIO Insider Trades

DENELSKY STEPHEN J bought 10.00K (~$48.70K) on Mar 17, 2026.
Snider William bought 8.47K (~$41.10K) on Mar 17, 2026.
Frost Mark T bought 5.00K (~$25.00K) on Mar 16, 2026.

HBIO Analyst Consensus

1 analysts cover HBIO: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.00.

Common questions about HBIO

Who owns HBIO stock?: Hedge funds tracked by Rallies that own HBIO include Panagora Asset. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Harvard Bioscience Inc.
Does Rallies show 13F holders for HBIO?: Yes. Rallies tracks hedge fund and 13F ownership data for HBIO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is HBIO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for HBIO. It does not provide personalized investment advice.